Nivolumab in melanoma

Exacerbation of Psoriasis During Nivolumab Therapy for Metastatic Melanoma

(2016) N Matsumura et al.   ACTA DERMATO-VENEREOLOGICA

Association of Acute Interstitial Nephritis With Programmed Cell Death 1 Inhibitor Therapy in Lung Cancer Patients

(2016) Anushree C. Shirali et al.   AMERICAN JOURNAL OF KIDNEY DISEASES

Effect of nivolumab on health-related quality of life in patients with treatment-naïve advanced melanoma: results from the phase III CheckMate 066 study

(2016) G. V. Long et al.   ANNALS OF ONCOLOGY

Acute renal allograft rejection after immune checkpoint inhibitor therapy for metastatic melanoma

(2016) L. Spain et al.   ANNALS OF ONCOLOGY

Serum lactate dehydrogenase as an early marker for outcome in patients treated with anti-PD-1 therapy in metastatic melanoma

(2016) S Diem et al.   BRITISH JOURNAL OF CANCER

Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy

(2016) S Bowyer et al.   BRITISH JOURNAL OF CANCER

Preclinical Rationale and Clinical Considerations for Radiotherapy Plus Immunotherapy

(2016) Jonathan E. Schoenhals et al.   CANCER JOURNAL

Myasthenic crisis and polymyositis induced by one dose of nivolumab

(2016) Toshihiro Kimura et al.   CANCER SCIENCE

Economic sustainability of anti-PD-1 agents nivolumab and pembrolizumab in cancer patients: Recent insights and future challenges

(2016) Francesca Tartari et al.   CANCER TREATMENT REVIEWS

Management of toxicities of immune checkpoint inhibitors

(2016) Lavinia Spain et al.   CANCER TREATMENT REVIEWS

Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma

(2016) Willy Hugo et al.   CELL

Therapeutic Monoclonal Antibodies for the Treatment of Chronic Obstructive Pulmonary Disease

(2016) Maria Gabriella Matera et al.   DRUGS

Nivolumab-induced hypophysitis in a patient with advanced malignant melanoma

(2016) Yudai Okano et al.   ENDOCRINE JOURNAL

Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor

(2016) V.R. Belum et al.   EUROPEAN JOURNAL OF CANCER

Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy

(2016) Lisa Zimmer et al.   EUROPEAN JOURNAL OF CANCER

Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy

(2016) Lars Hofmann et al.   EUROPEAN JOURNAL OF CANCER

Ipilimumab in melanoma

(2016) Pol Specenier   Expert Review of Anticancer Therapy

Risk of endocrine complications in cancer patients treated with immune check point inhibitors: a meta-analysis

(2016) Omar Abdel-Rahman et al.   Future Oncology

Nivolumab-induced organizing pneumonia in a melanoma patient

(2016) Tasuku Sano et al.   JAPANESE JOURNAL OF CLINICAL ONCOLOGY

Nivolumab-induced chronic inflammatory demyelinating polyradiculoneuropathy mimicking rapid-onset Guillain–Barré syndrome: a case report

(2016) Ryota Tanaka et al.   JAPANESE JOURNAL OF CLINICAL ONCOLOGY

Nivolumab-induced thyroid dysfunction

(2016) Ryota Tanaka et al.   JAPANESE JOURNAL OF CLINICAL ONCOLOGY

Metastatic Rhabdomyosarcoma: Still Room for Improvement

(2016) Leonard H. Wexler   JOURNAL OF CLINICAL ONCOLOGY

Autoimmune dermatologic toxicities from immune checkpoint blockade with anti-PD-1 antibody therapy: a report on bullous skin eruptions

(2016) George Jour et al.   JOURNAL OF CUTANEOUS PATHOLOGY

Case of de novo psoriasis possibly triggered by nivolumab

(2016) Susumu Murata et al.   JOURNAL OF DERMATOLOGY

Isolated adrenocorticotropic hormone deficiency possibly caused by nivolumab in a metastatic melanoma patient

(2016) Taku Fujimura et al.   JOURNAL OF DERMATOLOGY

Case of type 1 diabetes associated with less-dose nivolumab therapy in a melanoma patient

(2016) Yukiko Teramoto et al.   JOURNAL OF DERMATOLOGY

Constructing Tumor Vaccines Targeting for Vascular Endothelial Growth Factor (VEGF) by DNA Shuffling

(2016) Nana Bie et al.   JOURNAL OF IMMUNOTHERAPY

Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: A single-institution cohort

(2016) Shelley Ji Eun Hwang et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Organizing Pneumonia Induced by Nivolumab in a Patient with Metastatic Melanoma

(2016) Kazuhisa Nakashima et al.   Journal of Thoracic Oncology

Anti-PD1 Antibody Treatment and the Development of Acute Pulmonary Tuberculosis

(2016) Kohei Fujita et al.   Journal of Thoracic Oncology

Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial

(2016) Jeffrey S Weber et al.   LANCET ONCOLOGY

Bi-cytopenia possibly induced by anti-PD-1 antibody for primary malignant melanoma of the esophagus

(2016) Kyoko Inadomi et al.   MEDICINE

Ipilimumab in anti-PD1 refractory metastatic melanoma

(2016) Aurélie Jacobsoone-Ulrich et al.   MELANOMA RESEARCH

Autoimmune hemolytic anemia induced by anti-PD-1 therapy in metastatic melanoma

(2016) Benjamin Y. Kong et al.   MELANOMA RESEARCH

Severe Hyponatremia and Immune Nephritis Following an Initial Infusion of Nivolumab

(2016) Jeremy W. Vandiver et al.   Targeted Oncology

Nivolumab, an Anti-Programmed Cell Death-1 Antibody, Induces Fulminant Type 1 Diabetes

(2016) Yuka Miyoshi et al.   TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE

Emerging Tissue and Blood-Based Biomarkers that may Predict Response to Immune Checkpoint Inhibition

(2016) Claire F. Friedman et al.   Current Oncology Reports

Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy

(2016) Douglas B. Johnson et al.   Nature Communications

Fulminant type 1 diabetes mellitus with anti-programmed cell death-1 therapy

(2016) Masahide Okamoto et al.   Journal of Diabetes Investigation

Severe pneumonitis after nivolumab treatment in a patient with melanoma

(2016) Satoshi Watanabe et al.   ALLERGOLOGY INTERNATIONAL

Phase I/II Study of Metastatic Melanoma Patients Treated with Nivolumab Who Had Progressed after Ipilimumab

(2016) J. Weber et al.   Cancer Immunology Research

Autoimmune Bullous Skin Disorders with Immune Checkpoint Inhibitors Targeting PD-1 and PD-L1

(2016) J. Naidoo et al.   Cancer Immunology Research

Treatment of the Immune-Related Adverse Effects of Immune Checkpoint Inhibitors

(2016) Claire F. Friedman et al.   JAMA Oncology

Acute rhabdomyolysis with severe polymyositis following ipilimumab-nivolumab treatment in a cancer patient with elevated anti-striated muscle antibody

(2016) Mehmet Asim Bilen et al.   Journal for ImmunoTherapy of Cancer

Systemic inflammation in a melanoma patient treated with immune checkpoint inhibitors—an autopsy study

(2016) Viktor H. Koelzer et al.   Journal for ImmunoTherapy of Cancer

Thrombocytopenia due to low-dose colchicine therapy: A possible drug interaction with nivolumab and implications for supportive care

(2015) Lawrence R. Solomon   ACTA ONCOLOGICA

344OCost-effectiveness of nivolumab in combination with ipilimumab in patients with unresectable advanced melanoma in Australia

(2015) M.A. Bohensky et al.   ANNALS OF ONCOLOGY

Clinical outcomes of melanoma brain metastases treated with stereotactic radiation and anti-PD-1 therapy

(2015) K. A. Ahmed et al.   ANNALS OF ONCOLOGY

Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

(2015) R. Dummer et al.   ANNALS OF ONCOLOGY

Malignant melanoma showing a rapid response to nivolumab

(2015) Miho Tsutsumi et al.   AUSTRALASIAN JOURNAL OF DERMATOLOGY

Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes

(2015) M. Freeman-Keller et al.   CLINICAL CANCER RESEARCH

Risk of cutaneous toxicities in patients with solid tumors treated with immune checkpoint inhibitors: a meta-analysis

(2015) Omar Abdel-Rahman et al.   Future Oncology

Nivolumab: targeting PD-1 to bolster antitumor immunity

(2015) Julie R Brahmer et al.   Future Oncology

Strategies for combining immunotherapy with radiation for anticancer therapy

(2015) Steven N Seyedin et al.   Immunotherapy

Acetylcholine receptor binding antibody-associated myasthenia gravis and rhabdomyolysis induced by nivolumab in a patient with melanoma

(2015) Takushi Shirai et al.   JAPANESE JOURNAL OF CLINICAL ONCOLOGY

Serological aggravation of autoimmune thyroid disease in two cases receiving nivolumab

(2015) Tomohiko Narita et al.   JOURNAL OF DERMATOLOGY

Exacerbation of psoriasis vulgaris during nivolumab for oral mucosal melanoma

(2015) Y. Kato et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial

(2015) Jeffrey S Weber et al.   LANCET ONCOLOGY

Rapid Eradication of a Bulky Melanoma Mass with One Dose of Immunotherapy

(2015) Paul B. Chapman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab in Previously Untreated Melanoma without BRAF Mutation

(2015) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma

(2015) Michael A. Postow et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pembrolizumab versus Ipilimumab in Advanced Melanoma

(2015) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

(2015) James Larkin et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Cost Effectiveness Analysis of Nivolumab Compared to Ipilimumab for the Treatment of Braf Wild-Type Advanced Melanoma in Australia

(2015) M Bohensky et al.   VALUE IN HEALTH

Occurrence of Psoriasiform Eruption During Nivolumab Therapy for Primary Oral Mucosal Melanoma

(2015) Mikio Ohtsuka et al.   JAMA Dermatology

Subacute CNS Demyelination after Treatment with Nivolumab for Melanoma

(2015) C. Maurice et al.   Cancer Immunology Research

A systematic evaluation of abscopal responses following radiotherapy in patients with metastatic melanoma treated with ipilimumab

(2015) Ravi A Chandra et al.   OncoImmunology

Efficacy and Safety of Nivolumab in Patients With BRAF V600 Mutant and BRAF Wild-Type Advanced Melanoma

(2015) James Larkin et al.   JAMA Oncology

Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers

(2015) Luisa Carbognin et al.   PLoS One

Safety, Correlative Markers, and Clinical Results of Adjuvant Nivolumab in Combination with Vaccine in Resected High-Risk Metastatic Melanoma

(2014) G. T. Gibney et al.   CLINICAL CANCER RESEARCH

Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy

(2014) J. M. Taube et al.   CLINICAL CANCER RESEARCH

Ipilimumab Plus Sargramostim vs Ipilimumab Alone for Treatment of Metastatic Melanoma

(2014) F. Stephen Hodi et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab

(2014) Suzanne L. Topalian et al.   JOURNAL OF CLINICAL ONCOLOGY

High Procedure Volume Is Strongly Associated With Improved Survival After Lung Cancer Surgery

(2013) Margreet Lüchtenborg et al.   JOURNAL OF CLINICAL ONCOLOGY

Effect of a serogroup A meningococcal conjugate vaccine (PsA–TT) on serogroup A meningococcal meningitis and carriage in Chad: a community study

(2013) DM Daugla et al.   LANCET

APOL1 Risk Variants, Race, and Progression of Chronic Kidney Disease

(2013) Afshin Parsa et al.   NEW ENGLAND JOURNAL OF MEDICINE

Registry of Transcatheter Aortic-Valve Implantation in High-Risk Patients

(2012) Martine Gilard et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Recent trends in cutaneous melanoma incidence and death rates in the United States, 1992-2006

(2011) Ahmedin Jemal et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Immunotherapies in Clinical Trials: Do They Demand Different Evaluation Tools?

(2011) R. S. Tuma   JNCI-Journal of the National Cancer Institute

Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma

(2010) Ryosuke Hino et al.   CANCER

Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates

(2010) Julie R. Brahmer et al.   JOURNAL OF CLINICAL ONCOLOGY

Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria

(2009) J. D. Wolchok et al.   CLINICAL CANCER RESEARCH

Current systemic therapy for metastatic melanoma

(2009) Sanjiv S Agarwala   Expert Review of Anticancer Therapy

Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR–induced stop signal

(2009) Brian T Fife et al.   NATURE IMMUNOLOGY

PD-1 and Its Ligands in Tolerance and Immunity

(2008) Mary E. Keir et al.   Annual Review of Immunology